Avram Hershko

Director/Board Member at

The Marine Biological Laboratory

88 year

85 connections

Commercial Services

Health Technology

Consumer Services

Profile

Avram Hershko has been a Director of IVAX Corp.
since 2003.
He has been a Distinguished Professor since 1998 and Professor, Unit of Biochemistry, Faculty of Medicine since 1980, both at the Technion-Israel Institute of Technology in Haifa, Israel.
He was awarded a Nobel Prize in Chemistry in 2004.

Avram Hershko active positions

Companies	Position	Start
Technion-Israel Institute of Technology Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	01/01/1980
The Marine Biological Laboratory The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services Provides research and educational services	Director/Board Member	-

All active positions of Avram Hershko

Former positions of Avram Hershko

Companies	Position	End
IVAX LLC IVAX LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures & markets branded and generic pharmaceuticals	Director/Board Member	26/01/2006
Seed Therapeutics, Inc. Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang.	Founder	-

See the detail of Avram Hershko's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Avram Hershko's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
IVAX LLC IVAX LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures & markets branded and generic pharmaceuticals	Health Technology
Technion-Israel Institute of Technology Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Marine Biological Laboratory The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services Provides research and educational services	Commercial Services
Seed Therapeutics, Inc. Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang.	Commercial Services